Barry M. Massie

Barry M. Massie

Auto-generated profile, based on publicly available information

Barry M. Massie

School of Medicine University of California, and San Francisco VA Medical Center San Francisco California

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
BMBarry M. Massie
Barry M. Massie
PCPeter E. Carson
Peter E. Carson
JMJohn J. McMurray
John J. McMurray
MKMichel Komajda
Michel Komajda
RMRobert McKelvie
Robert McKelvie
APAgata Ptaszynska
Agata Ptaszynska
Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)

7 October 2010 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
BMBarry M. Massie
Barry M. Massie
COChristopher M. O'COnnor
Christopher M. O'COnnor
MMMarco I. Metra
Marco I. Metra
PPPiotr Ponikowski
Piotr Ponikowski
JTJohn R. Teerlink
John R. Teerlink
HDHoward C. Dittrich
Howard C. Dittrich
Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We tested the hypothesis that the use of rolofylline, an adenosine A1−receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure.

3 May 2013 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
SMSherry K. Milfred‐LaForest
Sherry K. Milfred‐LaForest
SCSheryl Chow
Sheryl Chow
RDRobert J. DiDomenico
Robert J. DiDomenico
KDKathleen Dracup
Kathleen Dracup
CEChristopher R. Ensor
Christopher R. Ensor
BMBarry M. Massie
Barry M. Massie

17 November 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
BMBarry M. Massie
Barry M. Massie
SASusan E. Ammon
Susan E. Ammon
JCJoseph F. Collins
Joseph F. Collins
WKWilliam F. Krol
William F. Krol
PAPaul W. Armstrong
Paul W. Armstrong
SWStuart Warren
Stuart Warren

31 May 2011 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
PDF file
MJMariell Jessup
Mariell Jessup
NANancy M. Albert
Nancy M. Albert
DLDavid E. Lanfear
David E. Lanfear
JLJoAnn Lindenfeld
JoAnn Lindenfeld
BMBarry M. Massie
Barry M. Massie
MZMark J. Zucker
Mark J. Zucker

9 September 2009 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
BMBarry M. Massie
Barry M. Massie